Getting to Know: Cochlear Limited

You could have bought a share of stock in Cochlear Limited at the turn of the century for about $10. A few days ago the stock was worth nearly $100 a share.

Cochlear Limited is the biggest of the three companies that dominate the cochlear implant market. More than a quarter of a million people have a Cochlear implant. Based in Australia, Cochlear Limited does most of its business in Europe and the U.S. through more than a dozen subsidiaries. With a billion dollars in annual revenue, the company features brands like Nucleus and Baha. In 2017, it reported $1,240 million in revenue (Australian). The company employs more than 4800 people in 50 countries. In 2022, Cochlear announced it was buying Danish competitor Oticon Medical for about $170 million (Australian).